Ticker
AGEN

Price
0.56
Stock movement up
+0.02 (3.73%)
Company name
Agenus Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
185.01M
Ent value
481.17M
Price/Sales
1.28
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-8.61%
1 year return
-64.33%
3 year return
-41.78%
5 year return
-28.42%
10 year return
-16.58%
Last updated: 2024-03-27

iO Charts is a Seeking Alpha partner

A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
March 14, 2024

iO Charts is a Seeking Alpha partner

DIVIDENDS

AGEN does not pay dividends or no data was received
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
March 13, 2024

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales1.28
Price to Book-
EV to Sales3.32
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
February 15, 2024

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count332.51M
EPS (TTM)-1.12
FCF per share (TTM)-1.22

Income statement

Loading...
Income statement data
Revenue (TTM)144.89M
Gross profit (TTM)44.35M
Operating income (TTM)-259.45M
Net income (TTM)-315.05M
EPS (TTM)-1.12
EPS (1y forward)-0.82

Margins

Loading...
Margins data
Gross margin (TTM)30.61%
Operating margin (TTM)-179.07%
Profit margin (TTM)-217.44%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash178.67M
Net receivables2.74M
Total current assets213.12M
Goodwill25.47M
Intangible assets6.23M
Property, plant and equipment0.00
Total assets413.56M
Accounts payable40.94M
Short/Current long term debt75.91M
Total current liabilities188.95M
Total liabilities474.83M
Shareholder's equity-61.28M
Net tangible assets159.25M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-271.22M
Capital expenditures (TTM)76.06M
Free cash flow (TTM)-342.73M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-76.18%
Return on Invested Capital654.72%
Cash Return on Invested Capital712.26%
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
January 22, 2024

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.54
Daily high0.56
Daily low0.54
Daily Volume3.57M
All-time high315.75
1y analyst estimate7.06
Beta1.49
EPS (TTM)-1.12
Dividend per share-
Ex-div date-
Next earnings date7 May 2024

Downside potential

Loading...
Downside potential data
AGENS&P500
Current price drop from All-time high-99.82%-
Highest price drop-99.83%-56.47%
Date of highest drop18 Mar 20249 Mar 2009
Avg drop from high-93.07%-11.36%
Avg time to new high2025 days13 days
Max time to new high6051 days1805 days
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
November 30, 2023

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
AGEN (Agenus Inc) company logo
Marketcap
185.01M
Marketcap category
Small-cap
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Employees
533
SEC filings
CEO
Garo H. Armen
Country
USA
City
Lexington
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
November 7, 2023

iO Charts is a Seeking Alpha partner

A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
November 6, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
August 23, 2023
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
August 9, 2023
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
August 8, 2023
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
August 7, 2023
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
May 9, 2023
A high-level overview of Agenus Inc. (AGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
May 8, 2023
iO Charts is a Seeking Alpha partnerNext page